New Zealand appears to be a well-funded healthcare system when compared to other OECD nations, despite persistent claims from advocacy groups suggesting otherwise. These groups often portray New Zealand as underfunding healthcare, creating public pressure for increased government spending. However, data reveals New Zealand ranks within the top half of OECD countries for government healthcare contributions. This discrepancy raises questions about the motivations behind these intensive advocacy campaigns. The article suggests a potential link between pharmaceutical companies and these campaigns, implying that increased funding benefits the industry’s profits. Ultimately, the piece hints at a coordinated effort to influence public opinion and drive up healthcare expenditure, benefiting pharmaceutical giants rather than necessarily improving patient access.